摘要
目的探讨非诺贝特及辛伐他丁对混合型高脂血症的疗效作用差异,为临床用药提供指导。方法将在我院接受治疗的54例混合型高脂血症患者随机分为联合治疗组、非诺贝特组和辛伐他丁组各18例,联合治疗组组患者使用非诺贝特联合辛伐他丁进行治疗,非诺贝特组使用非诺贝特进行治疗,辛伐他丁组使用辛伐他丁进行治疗,检测血清总胆固醇(TC)、三酰甘油(TG)、高、低密度脂蛋白(HDL-C、LDL-C来评价药物疗效差异。结果非诺贝特组LDL-C的含量与联合治疗组比较具有显著性差异(**P<0.01),辛伐他丁组与联合治疗组比较TG、HDL-C含量具有显著性差异(*P<0.05或**P<0.01);与非诺贝特组比较,辛伐他丁组TG、HDL-C、LDL-C含量具有显著性差异(#P<0.05)。结论非诺贝特较辛伐他丁其降低TG、升高HDL-C作用较强,对TC也具有一定的降低作用,辛伐他丁较非诺贝特其降低TC、降低LDL-C作用较强。
Objective To discuss the effect difference between fenofibrate and simvastatin on mixed hyperlipidaemia,and provide directions for clinical therapy.Methods 54 cases of mixed hyperlipidaemia patients who were admittted into our hospital were divided into combined treating group,fenofibrate group and simvastatin group randomly,each group had 18 cases.The combined treating group was treated with fenofibrate combined with simvastatin,the fenofibrate group was treated with fenofibrate and the simvastatin group was treated with simvastatin,the TC,TG,HDL-C,LDL-C levels in serum were selected for the drug effect evaluation.Results The LDL-C serum level of fenofibrate group compared with combined treating group had a significant difference（＊＊P0.01）,the TG,HDL-C serum level of simvastatin compared with combined treating group had a significant difference（＊P0.05 or ＊＊P0.01）,the TG,HDL-C,LDL-C serum level of simvastatin compared with fenofibrate group had a significant difference（#P0.05）.Conclusion Fenofibrate has a decreasing TG,increasing HDL-C effect superior to simvastatin,in addition,has some content of decreasing TC effect.Simvastatin has a decreasing TC,LDL-C effect superior to fenofibrate.
出处
《中国医药指南》
2012年第31期41-42,共2页
Guide of China Medicine
